Britain and America have finalized a landmark trade agreement that will maintain zero duties on UK pharmaceutical exports entering the American market.
Agreement Details of the Pact
As part of the deal, the UK has pledged to boost expenditure on pharmaceuticals through the NHS. This move secures that tariffs on these key goods will remain at nothing for a duration of three years.
This agreement comes after previous statements to dramatically increase tariffs on patented pharmaceutical imports, with potential rates discussed as high as 100%.
"This arrangement between the United Kingdom reinforces the global environment for innovative medicines and establishes much-needed fairness to transatlantic medicine commerce," an announcement noted.
Trade Importance
Drugs represent one of the the United Kingdom's most significant goods shipped to the America, which is clearly the primary destination for large UK drugmakers.
Trade data indicate that in the one-year period to the end of the third quarter, the UK exported drugs valued at over eleven billion pounds to the US. This amount represented 17.4% of total UK exports in that period.
"This agreement safeguards jobs, increases investment and sets the stage for the UK to emerge as a international leader for medical research," a minister commented.
Specific NHS Changes
The agreement entails several notable changes from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it considers new treatments to be unaffordable by 25%.
- Increased NHS Spending: There is a goal to raise overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to stay within budget will be restricted at 15%. In the past, refunds were more than 20%.
Broader Context
This agreement comes amid a long-running tension between the drug companies and the UK government over drug pricing and regulatory access.
These tensions were exacerbated by assertions that US consumers were paying a premium for the same drugs than people in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar expansions have been directed toward projects in the United States.
One official publicly accepted that the NHS had to invest a greater share on treatments, noting that its budget allocation on drugs had decreased as a proportion of its total funding over the previous ten-year period.
